Evaluate Ltd

Is liver health the next multi-billion dollar breakthrough therapy area? By the end of the decade, the MASH market could surpass $9.5bn. What's in the pipeline and who are the players to watch? https://lnkd.in/e8FyV3Vt

FDA approvals picked up the pace in Q3 and there are some big commercial expectations for several of the 13 newly-approved drugs. In his latest article for Nature, Paul Verdin reports that this cohort is anticipated to achieve sales of nearly $12bn in 2030, with neurology/psychiatry leading the way. Subscription may be required. #pharma #biopharma #drugapprovals https://ow.ly/PLV450TTgUu

Accelerating decisions. Advancing treatments. 74 billion data points and AI-driven insights. Introducing NorstellaLinQ: https://ow.ly/cBc350TGfr5. Get closer to the patient than ever before. Learn more about NorstellaLinQ from Norstella at the link in this post.

BIO-Europe is fast approaching and the Evaluate Ltd team are attending. Come visit us at booth #82 and grab your copy of our dealmaking analysis report. We look forward to seeing you there! Book a meeting: https://ow.ly/uP7g50TSq8Z

Join us for a session on the strategic value of Competitive Intelligence. 👉 https://ow.ly/rogu50TQBpu Gain exclusive insights from our expert on how to: 💪 Strengthen cross-functional relationships, improve efficiency, and save time. 🤝 Empower stakeholders to better understand and leverage CI. 👀 Increase the visibility and use of CI across your organisation. 📈 Ensure access to the latest information and insights. 💊 Effortlessly track critical market signals and clinical updates.

NorstellaLinQ has tagged 1.5 million records to 55 custom and standard ontologies, from indication, dosage route, mechanism of action and drug target, spanning the full lifecycle to help surface insights and recommendations. https://ow.ly/5R7350TEWGY With hundreds of MDs, epidemiologists, PhDs, pharmacists, RNs, technologists and data scientists, Norstella can synthesize vast datasets to offer faster, more actionable insights. Get closer to the patient than ever before. Learn more about NorstellaLinQ from Norstella, the parent company of Evaluate Ltd, at the link in this post.

【HMIC講演 参加ありがとうございました✨】 -English below 本日、#HMIC カンファレンス2024にて#Evaluate スポンサード講演をさせていただきました。🎤✨ 製薬業界に深い知見をもつ弊社Principal Consultantの砂押その子が、データドリブンな#UnmetNeeds 分析について事例を交えて講演し、多くの皆様にご参加いただきました。 貴重なご意見やご質問をいただき、誠にありがとうございました。 〇講演で使用したリアルワールドデータについてはこちら👉 https://lnkd.in/gn5d4Hrn 〇HMICの詳細は以下のリンクからご覧いただけます。👉 https://lnkd.in/gMhcamxb #エバリュエート #製薬業界 #ポートフォリオ戦略 #リスクマネジメント #patientjourney --------------------------- I had the pleasure of giving an #Evaluate sponsored talk today at #HMIC Conference 2024. 🎤✨ Our Principal Consultant, Sonoko Sunashi, who has deep knowledge of the pharmaceutical industry, gave a presentation on data-driven #UnmetNeeds analysis with case studies, which was well attended. Thank you very much for your valuable comments and questions. -For more information about the real-world data used in the lecture, click here 👉 https://lnkd.in/gn5d4Hrn -For more information about HMIC, please click on the following link. 👉 https://lnkd.in/gMhcamxb #evaluate #pharma #portfolio #riskmanagement #patientjourney

Looking to strengthen your drug pipeline with some in-licensed assets? Our expert consultants have some guidance to ensure that you identify the assets that align with your strategy. Check out our best practices webinar now - it's 15 minutes very well spent! https://ow.ly/6a9r50TPEQj

【BioJapanご来場の御礼】 先日は、#BioJapan2024 にご来場いただき、誠にありがとうございました✨ 今年はブース初出展でしたが、皆様のおかげで、大変盛況のうちに終了することができました。 特にセミナーは登録時点で満席となり、多くの方々にご参加いただけたことを大変嬉しく思います。新たな出会いや貴重なご意見をいただき、心より感謝申し上げます。 これからも皆様と共に、データの観点から、創薬・バイオテクノロジーの未来を切り拓いていきたいと考えております🧬✨ 引き続きご支援のほど、よろしくお願い申し上げます。 #BioJapan2024 #BioJapan #バイオテクノロジー #バイオジャパン #創薬支援 #Evaluate #Citeline #エバリュエート #サイトライン

NorstellaLinQ supports multiple teams across biopharma. Get closer to the patient than ever before. Learn more about NorstellaLinQ from Norstella, the parent company of Evaluate Ltd: https://ow.ly/BIn750TOw9T.